News | April 09, 2009

NMT Medical’s STARFlex PMA Approved as Ventricular Septal Defect Repair Implant

April 9, 2009 - NMT Medical Inc. has received Pre-Market Approval (PMA) from the FDA to being commercial sales of the STARFlex cardiac septal repair implant for patients with ventricular septal defects (VSD).

STARFlex is constructed from a low profile, MP35N framework to which a knitted Dacron fabric is securely attached. The implant can be placed in the heart to close the VSD using a catheter during a minimally invasive procedure in the cath lab, providing an alternative to open-heart surgery.

Using spring coils in the framework, the STARFlex implant can be collapsed into a catheter for insertion into the heart. Once inserted through the catheter, the STARFlex implant is opened, with one umbrella positioned on each side of the defect. The design of the frame reportedly allows the device to conform to variations in the anatomy of the septum, keeping a low profile without obstructing the flow of blood through the atria.

For information: www.nmtmedical.com.

Related Content

Earlier Intervention for Mitral Valve Disease May Lead to Improved Outcomes
News | Heart Valve Technology | July 26, 2018
The number of patients undergoing mitral valve operations are at an all-time high, and new research suggests many...
The Abbott Tendyne transcatheter mitral valve replacement (TMVR) system  is being tested in the SUMMIT Trial.

The Abbott Tendyne transcatheter mitral valve replacement (TMVR) system.

Feature | Heart Valve Technology | July 26, 2018
July 26, 2018 — The pivotal clinical study in the U.S.
A CoreValve TAVR valve seen in a CT scan looking down from the aortic arch into the left ventricle using reconstruction software from TeraRecon.

A CoreValve TAVR valve seen in a CT scan looking down from the aortic arch into the left ventricle using reconstruction software from TeraRecon.

Feature | Heart Valve Technology | July 26, 2018
July 26, 2018 — A new multi-societal expert consensus document has been released that summarizes the position of thes
Abbott Receives FDA Approval for Third-Generation MitraClip Device
Technology | Heart Valve Technology | July 18, 2018
July 18, 2018 — Abbott announced it received approval from the U.S.
Videos | Heart Valve Technology | July 18, 2018
Jonathon Leipsic, M.D., FSCCT, professor of radiology and cardiology at the University of British Columbia, Vancouver
Videos | Heart Valve Technology | July 10, 2018
Ori Ben-Yehuda, M.D., executive director of the Cardiovascular Research Foundation Clinical Trial Center, discusses t
Videos | Heart Valve Technology | July 05, 2018
Rebecca Hahn, M.D., professor of medicine and director of interventional echocardiography, Columbia University Medica
Henry Ford Hospital First in Michigan to Perform Cardioband Mitral Valve Procedure

An angiography image showing the catheter-based implantation of the Cardioband annuloplasty ring using corkscrew shaped anchors.

News | Heart Valve Technology | June 13, 2018
Henry Ford Hospital is one of 17 U.S. trial sites using a catheter-based procedure approved in Europe to repair a leaky...
Abbott Portico transcatheter aortic valve replacement (TAVR) performed well PORTICO I real-world study. #EuroPCR
News | Heart Valve Technology | June 01, 2018
June 1, 2018 –  Use of the Abbott Portico transcatheter aortic valve replacement (TAVR) therapy was associated with e
Tendyne Transcatheter Mitral Valve Replacement Device Demonstrates Positive 30-Day Outcomes
News | Heart Valve Technology | May 25, 2018
Abbott announced favorable outcomes from the first 100 patients treated in a global study of its Tendyne Transcatheter...
Overlay Init